2025. Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study. SKIN The Journal of Cutaneous Medicine. 9, 4 (Jul. 2025), s582. DOI:https://doi.org/10.25251/gdd40x24.